SOBI and SOBI.ST Related Headlines
Go Back- Sobi reports positive phase 3 trial results for gout drug pozdeutinurad
- Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout
- Sobi to acquire Arthrosi for $950 million to expand gout treatments
- Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
SOBI and SOBI.ST Related Press Releases
Go Back- Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout
- Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
